Open session of the standing technical committee of the EUFMD- 2004

Page 198

Appendix 28 Role of European Food Safety Authority (EFSA) and current tasks related to FMD Jordi Serratosa* Scientific coordinator of the Panel on Animal Health and Wefare. European food safety Authority. Rue de Geneve 10 -6/05; 1140 Evere, Brussels (Belgium) Jordi.serratosa@efsa.eu.int Objectives: to present the risk assessment tasks of EFSA and the FMD related activities. Introduction: Following a series of food scares in the 1990s (eg BSE, dioxins… which under-mined consumer confidence in the safety of the food chain, the European Union concluded that it needed to establish a new scientific body charged with providing independent and objective advice on food safety issues associated with the food chain. Its primary objective as set out in the White Paper on Food Safety would be to:” contribute to a high level of consumer health protection in the area of food safety, through which consumer confidence can be restored and maintained. ”The result was EFSA. EFSA was legally born from the European Parliament and Council regulation (EC) No 178/2002 of 28 January 2002. The new Authority quickly found its feet, organising its first Management Board meeting 9 months later under the Chairmanship of S. Slorach. Shortly afterwards it nominated its first Executive Director, G. Podger, and created the Advisory Forum, made up of representatives from food safety bodies in the Member States. EFSA truly opened for business in May 2003, with the establishment of its Scientific Committee and Panels. World-class scientists from all over Europe were appointed to eight Panels, covering everything from food additives to animal health, and to a Scientific Committee with oversight of these panels. Now as we approach the end of 2004, staff numbers have doubled and continue to increase, EFSA has published over a hundred opinions and steadily carries on with its push to establish itself permanently in Parma, Italy. EFSA provides independent scientific advice on all matters linked to food and feed safety -including animal health and welfare and plant protection - and provides scientific advice on nutrition in relation to Community legislation. The Authority communicates to the public in an open and transparent way on all matters within its remit. EFSA’s risk assessments provide risk managers (consisting of EU institutions with political accountability, i.e. European Commission, European Parliament and Council) with a sound scientific basis for defining policy driven legislative or regulatory measures required to ensure a high level of consumer protection with regards to food safety. Overall capacity-building is set to continue, enabling the Authority to meet work programme commitments including the significant expansion of both its scientific and communications activities as well as the development of its institutional, stakeholder and international relations. EFSA is currently dealing principally with requests for risk assessments from the European Commission and plans to take on a wider brief from other European institutions in the near future. Notwithstanding the important needs of its key customers, EFSA is already undertaking its own work in order to look ahead and address broader issues of importance to its mandate. For example, through such “selftasking”, the Authority’s Scientific Committee has initiated work in relation to the identification of emerging food safety issues. Discussion on FMD activities: For many years now in Europe and worldwide, the most commonly accepted way of protecting disease-free areas from the risk of outbreaks of epizootic animal diseases has been to guard borders through strict controls on imports of live animals and products of animal.

189


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix 82

17min
pages 492-500

Appendix 77

22min
pages 468-476

Appendix 78

25min
pages 477-484

Appendix 79

14min
pages 485-489

Appendix 81

1min
page 491

Appendix 80

1min
page 490

Appendix 76

12min
pages 464-467

Appendix 75

1min
page 463

Appendix 64

10min
pages 412-414

Appendix 72

13min
pages 455-460

Appendix 73

1min
page 461

Appendix 65

1min
page 415

Appendix 67

1min
page 424

Appendix 63

34min
pages 401-411

Appendix 62

2min
page 400

Appendix 54

8min
pages 361-363

Appendix 61

15min
pages 394-399

Appendix 55

11min
pages 364-366

Appendix 59

1min
page 385

Appendix 60

20min
pages 386-393

Appendix 56

1min
page 367

Appendix 42

21min
pages 270-276

Appendix 52

10min
pages 350-352

Appendix 50

21min
pages 330-339

Appendix 46

2min
page 307

Appendix 37

7min
pages 241-243

Appendix 38

7min
pages 244-246

Appendix 41

2min
page 269

Appendix 40

15min
pages 255-268

Appendix 36

16min
pages 236-240

Appendix 35

15min
pages 231-235

Appendix 34

25min
pages 224-230

Appendix 28

2min
page 198

Appendix 31

10min
pages 212-215

Appendix 29

16min
pages 199-203

Appendix 33

3min
pages 221-223

Appendix 27

1min
page 197

Appendix 26

27min
pages 188-196

Appendix 25

12min
pages 182-187

Appendix 23

8min
pages 168-171

Appendix 22

28min
pages 158-167

Appendix 15

2min
page 113

Appendix 16

7min
pages 114-116

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

4min
pages 144-145

Appendix 19

18min
pages 136-143

Appendix 14

4min
page 112

Appendix 13

10min
pages 107-111

Appendix 5

2min
page 64

Appendix 12

9min
pages 104-106

Appendix 3

9min
pages 47-49

Appendix 4

26min
pages 50-63

Appendix 8

12min
pages 77-80

Appendix 2

8min
pages 43-46

Open Session

6min
pages 39-42

Closed Session

2min
pages 37-38

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

3min
page 33

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

3min
page 36

Item 14 – Regulatory compliance

2min
page 35

Item 10 – International issues

3min
page 32

Item 9 – Novel vaccines

3min
page 31

Item 7 – Optimisation of conventional vaccines

3min
page 29

Item 4 – Managing diagnostic demands

3min
page 27

Item 8 – Regulatory issues affecting FMD vacine selection and use

3min
page 30

Item 3 – Transmission and its control

3min
page 26

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

3min
page 16

Item 1 – Recent findings in molecular epidemiology of FMDV

3min
page 24

Item 2 – Surveillance: for what purpose and how much is enough?

3min
page 25

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection

3min
page 20
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.